SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
AND EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000
COMMISSION FILE NUMBER 001-15431
THE PLASTIC SURGERY COMPANY
(Exact Name of Registrant as Specified in its Charter)
GEORGIA 58-2317410
(State or Other Jurisdiction (I.R.S. Employer
of Incorporation or Organization) Identification Number)
104 WEST ANAPAMU STREET, SUITE G
SANTA BARBARA, CALIFORNIA 93101
TELEPHONE: (805) 963-0400
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. YES [X] NO[ ]
As of March 31, 2000, the registrant had 4,553,708 shares of common stock
outstanding.
<PAGE>
THE PLASTIC SURGERY COMPANY
FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2000
<TABLE>
INDEX
<CAPTION>
<S> <C> <C>
PART I FINANCIAL INFORMATION
Item 1 Financial Statements and General Information ................................................................... 3 - 5
Balance Sheets as of March 31, 2000 (unaudited) and December 31, 1999 .......................................... 3
Statement of Operations for the Three Months Ended March 31, 2000
(unaudited) and March 31, 1999 (unaudited)...................................................................... 4
Statement of Cash Flows for the Three Months Ended March 31, 2000
(unaudited) and March 31, 1999 (unaudited)...................................................................... 5
Notes to Financial Statements .................................................................................. 6 - 8
Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations........................... 9 - 12
Item 3 Quantitative and Qualitative Disclosure About Market Risk....................................................... 12
PART II OTHER INFORMATION
Item 1 Legal Proceedings............................................................................................... 13
Item 6 Exhibits and Reports on Form 8-K................................................................................ 13
</TABLE>
2
<PAGE>
THE PLASTIC SURGERY COMPANY
PART I
FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
BALANCE SHEETS
(UNAUDITED)
December 31, March 31,
1999 2000
------------- -------------
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash and cash equivalents ............................ $ 842,307 $ 374,317
Accounts receivable .................................. 160,140 797,744
Other current assets ................................. -- 34,587
------------- -------------
Total current assets ............................... 1,002,447 1,206,648
------------- -------------
EQUIPMENT, at cost ..................................... 1,196,865 1,231,221
Less accumulated depreciation ........................ (49,285) (100,820)
------------- -------------
Equipment, net .................................... 1,147,580 1,130,401
------------- -------------
INTANGIBLE ASSETS ...................................... 9,294,504 9,294,504
Less accumulated amortization ........................ (142,330) (310,676)
------------- -------------
Intangible assets, net ............................ 9,152,174 8,983,828
------------- -------------
OTHER ASSETS ........................................... -- 71,316
------------- -------------
Total assets ................................. $ 11,302,201 $ 11,392,193
============= ============
LIABILITIES AND SHAREHOLDERS'
EQUITY
CURRENT LIABILITIES:
Accounts payable ..................................... $ 558,041 $ 450,153
Accrued employee and consultant compensation ......... 1,928,443 2,043,304
Current portion of long-term debt .................... 1,952,557 1,919,147
------------- -------------
Total current liabilities .................... 4,439,041 4,412,604
LONG-TERM DEBT ......................................... 4,203,565 3,954,697
------------- -------------
Total liabilities ................................... 8,642,606 8,367,301
------------- -------------
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Common stock; no par value; 100,000,000 shares
authorized, and 4,553,708 shares issued and
outstanding at December 31, 1999 and March 31, 2000 -- --
Paid-in capital ...................................... 36,450,529 36,450,529
Warrants ............................................. 8,714,754 8,714,754
Accumulated deficit .................................. (42,505,688) (42,140,391)
------------- -------------
Total shareholders' equity ................... 2,659,595 3,024,892
------------- -------------
Total liabilities and shareholders' equity ... $ 11,302,201 $ 11,392,193
============= ============
</TABLE>
The accompanying notes are an integral part of these statements.
3
<PAGE>
THE PLASTIC SURGERY COMPANY
STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three For the Three
Months Ended Months Ended
March 31, 1999 March 31, 2000
-------------- --------------
Net revenues ................................... $ -- 7,638,518
Direct expenses:
Salaries, wages, and benefits ................ -- 1,831,327
Medical supplies ............................. -- 850,825
Advertising .................................. -- 640,801
Rent ......................................... -- 727,234
-------------- --------------
Total direct expenses ..................... -- 4,050,187
Salaries, wages and benefits ................... 240,468 360,145
General operating expenses ..................... 199,511 2,486,585
Depreciation and amortization .................. 2,288 227,907
-------------- --------------
Total operating expenses ..................... 442,267 7,124,824
-------------- --------------
Operating margin ............................... (442,267) 513,694
Other income ................................. 3,776 7,145
Interest expense ............................. -- (119,118)
-------------- --------------
Net income (loss) before taxes ................. (438,491) 401,721
Provision for income taxes ................... -- 36,424
-------------- --------------
Net income (loss) after taxes .................. $ (438,491) $ 365,297
============== ==============
Basic net income (loss) per share .............. $ (22.77) $ 0.08
============== ==============
Weighted average basic shares outstanding ...... 19,258 4,553,708
============== ==============
Diluted net income (loss) per share ............ $ (22.77) $ 0.08
============== ==============
Weighted average diluted shares outstanding .... 19,258 4,865,061
============== ==============
The accompanying notes are an integral part of these statements.
4
<PAGE>
<TABLE>
THE PLASTIC SURGERY COMPANY
STATEMENTS OF CASH FLOWS
(UNAUDITED)
<CAPTION>
For the Three For the Three
Months Ended Months Ended
March 31, 1999 March 31, 2000
-------------- --------------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) ........................................ $ (438,491) $ 365,297
Adjustments to reconcile net income to net cash
used in operating activities:
Loss on disposal of property and equipment ............. -- 7,603
Proceeds from sale of property and equipment ........... -- 600
Depreciation and amortization .......................... 2,288 227,907
Changes in assets and liabilities:
Accounts receivable .................................. -- (637,604)
Other current assets ................................. -- (34,587)
Other assets ......................................... -- (71,316)
Accounts payable ..................................... 28,600 (107,888)
Accrued employee and consultant compensation ......... 74,083 114,861
-------------- --------------
Total adjustments ................................. 104,971 (500,424)
-------------- --------------
Net cash used in operating activities ............. (333,520) (135,127)
-------------- --------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment ....................... (2,327) (50,585)
-------------- --------------
Net cash used in investing activities ............. (2,327) (50,585)
-------------- --------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock sold to investors .................... 237,000 --
Payment of debt .......................................... -- (282,278)
-------------- --------------
Net cash provided by (used in) financing activities 237,000 (282,278)
-------------- --------------
NET CHANGE IN CASH AND CASH
EQUIVALENTS .............................................. (98,847) (467,990)
CASH AND CASH EQUIVALENTS,
Beginning of period ...................................... 402,860 842,307
-------------- --------------
CASH AND CASH EQUIVALENTS, end of period ................... $ 304,013 $ 374,317
============== ==============
</TABLE>
The accompanying notes are an integral part of these statements.
5
<PAGE>
THE PLASTIC SURGERY COMPANY
NOTES TO FINANCIAL STATEMENTS
1. BUSINESS AND ORGANIZATION
Organization
The Plastic Surgery Company (the "Company") was incorporated as a Georgia
corporation on April 30, 1997 to provide business development services and
Internet solutions to plastic surgery practices. The Company had no significant
operations until the closing of an initial public offering (the "Offering") on
December 10, 1999.
Upon the closing of the Offering, the Company effected the transfer (the
"Transfer"), of certain operating assets and certain liabilities of, or the
stock of an entity holding certain assets and certain liabilities of, plastic
surgery practice entities (the "Founding Practices") in exchange for cash, notes
and shares of common stock. Each Founding Practice transaction was individually
negotiated between the Company and the Founding Practice as to all material
terms. The Company also entered into long-term business services agreements with
these Founding Practices.
The Company accounted for certain of the Founding Practices acquired in the
Transfers under Staff Accounting Bulletin No. 48, "Transfers of Nonmonetary
Assets by Promoters and Shareholders" ("SAB 48"). The shareholders of these
Founding Practices are considered promoters. For each Transfer accounted for
under SAB 48, the Founding Practice received up to a maximum of 25% of the total
consideration for each transaction in cash and notes and the balance in
2,812,963 shares of common stock valued at the initial public offering price.
The cash paid to the Founding Practices accounted for under SAB 48 was recorded
as a dividend by the Company and the assets and liabilities acquired were
recorded at their historical costs. For the Transfers not accounted for under
SAB 48, the Company recorded the Transfers at fair value as asset acquisitions
and recorded intangible assets amortized over periods ranging from 10 to 15
years.
Basis of Presentation
The financial statements included herein have been prepared in accordance
with rule 10-01 of Regulation S-X. Pursuant to applicable regulations of the
Securities and Exchange Commission (the "SEC"), the information at March 31,
2000 and for the three-month periods ended March 31, 2000 and 1999 is unaudited.
Certain information and footnote disclosures normally included in financial
statements prepared in accordance with accounting principles generally accepted
in the United States have been condensed or omitted. The financial statements
reflect all elimination entries and normal adjustments that are necessary for a
fair presentation of the results for the interim period ended March 31, 2000 and
March 31, 1999. In the opinion of management, the accompanying condensed
financial statements include the accounts of the Company and all adjustments
necessary to present fairly the Company's financial position at March 31, 2000
and December 31, 1999, and its results of operations and cash flows for the
three months ended March 31, 2000 and March 31, 1999.
Operating results for interim periods are not necessarily indicative of the
results for full years. These condensed financial statements should be read in
conjunction with the financial statements of The Plastic Surgery Company and
related notes thereto, and management's discussion and analysis related thereto,
all of which are included in the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 1999.
The Company currently does not consolidate the operations of the practices
that it manages because the arrangements do not meet the requirements for
consolidation as set forth in Emerging Issues Task Force 97-2.
Prior Year Reclassifications
Certain prior year amounts have been reclassified to conform to current
year presentation.
6
<PAGE>
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - REVENUE RECOGNITION
The Company recognizes revenue in amounts equal to the operating expenses
of the practices assumed by the Company plus service fees of approximately 15%
of the net cash collected by the practices. Net cash collected is defined as
revenue resulting from fees and charges for each month earned and collected by
and on behalf of each practice as a result of professional services provided by
the practice's surgeons and those under the surgeons' supervision and other fees
or income generated by the practice, less any adjustments for refunds or other
items that do not generate a fee. The amount of operating expenses of the
practices assumed by the Company was as follows:
For the three months ended March 31, 1999 $ 0
For the three months ended March 31, 2000 $ 6,250,220
3. SUBSEQUENT EVENTS
In February 2000, the Company executed a letter of intent to acquire a 51%
ownership of Lynx Medical Systems ("Lynx") patient management software.
Anticipated consideration includes $100,000 cash and options to purchase 50,000
shares of the Company's common stock. The options will vest ratably over the
next four years. For a period of three years, the Company may purchase the
remaining interest in the software. Lynx provides marketing and patient
management software to the plastic surgery industry.
In February 2000, the Company announced a plan to develop a national chain
of medically oriented skin care clinics in a joint venture with Elizabeth Grady
companies, which owns and operates the largest chain of skin care clinics in the
United States. In the agreement between the parties, the Elizabeth Grady
Companies will provide established operating systems and a recognized brand of
skin care products to the development of medically-oriented skin care clinics,
which will be linked to The Plastic Surgery Company's national network of
affiliated board certified plastic surgery practices.
Equipment
Equipment is stated at cost less accumulated depreciation. Depreciation is
provided using the straight-line method over the assets' estimated useful lives
of five to seven years.
Three-Month Period
Ended March 31,
1999 2000
---------------------------
Equipment consisted of the following:
Computer equipment and hardware $ 24,241 $ 354,767
Furniture and fixtures 23,846 201,393
Medical equipment 427,417
Leasehold improvements 247,644
------------ ------------
48,087 1,231,221
Less accumulated depreciation (10,809) (100,820)
------------ ------------
$ 37,278 $ 1,130,401
------------ ------------
Intangible Assets
Intangible assets consist of the excess of the purchase price over the fair
value of the net assets acquired from the asset acquisitions at fair value and
the purchase of contract rights discussed below. For the acquired practices, the
business services agreements have terms of 20 to 25 years. The Company has
allocated these intangible assets to the value obtained through entering into
business services agreements. The Company believes that no other identifiable
intangible asset was generated by these acquisitions. The Company amortizes the
intangible assets over their estimated useful lives taking into consideration
various qualitative factors, including the terms of the business services
agreements. The Company considers the unique characteristics of each practice
being managed and uncertainties resulting from the Company's inability or the
practices' inability to perform over the term of the applicable business
services agreement. These factors take into consideration the probability that a
practice will be able to extend its existence indefinitely and thus enable the
Company to recover through profitable operations the carrying value of the
intangible assets.
7
<PAGE>
The Company is amortizing intangible assets related to the acquisitions of
allied practices or allied practice assets over periods ranging from 10 to 15
years. Amortization expense related to these intangible assets for the period
from inception (April 30, 1997) to December 31, 1997 and for the years ended
December 31, 1998 and 1999 was $0, $0 and $22,613. Amortization expense for the
first quarter ended March 31, 2000 was $168,346.
Debt
The Company's debt consisted of the following at March 31, 2000:
<TABLE>
<CAPTION>
Current Long Term
------- ---------
<S> <C> <C>
Advance from shareholder, non-secured,
Zero interest $ 55,000 $ --
Note payable to shareholder, non-secured,
Zero interest 994,512 --
Notes payable to allied practices, 8% interest 869,635 3,954,697
------------- -------------
$ 1,919,147 $ 3,954,697
------------- -------------
</TABLE>
Earnings per share
Basic earnings per share represents net earnings divided by the
weighted-average number of common shares outstanding for the period. Diluted
earnings per share represents net earnings divided by the weighted-average
number of shares outstanding including the dilutive impact of common stock
equivalents calculated using the treasury stock method. For the three-month
period ended March 31, 2000, the difference between the weighted-average number
of shares used in the basic computation compared to that used in the diluted
computation was due to the dilutive impact of options and warrants to purchase
common stock.
The reconciliation of basic to diluted weighted-average shares are as
follows:
Three-month period
Ended March 31, 2000
--------------------
Net earnings $ 365,297
-----------
Weighted-average shares used in basic computation 4,553,708
Dilutive stock options and warrants 311,353
-----------
Weighted-average shares used for dilutive
computation 4,865,061
8
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
The following discussion and analysis contains certain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as amended (the
"1934 Act"). Although we believe that our expectations are based on reasonable
assumptions, we can give no assurance that our goals will be achieved. The
important factors that could cause actual results to differ materially from
those in the forward-looking statements herein include, without limitation, our
ability to grow through affiliations with additional allied practices, our
ability to identify suitable affiliation candidates and to profitably manage or
successfully integrate new allied practices with us and our existing practices,
our ability to secure capital, and the related cost of such capital, needed to
fund our future growth, regulatory development and changes in the United States
healthcare system and medical profession that may affect our profitability or
the enforceability of our agreements with the allied practices and the other
factors detailed in our Annual Report on Form 10-K for the year ended December
31, 1999 filed with the Securities and Exchange Commission.
OVERVIEW
On December 15, 1999 we began providing business development services and
Internet solutions to our alliance of 30 board-certified or board-eligible
plastic surgeons and one surgeon certified by the Canadian Board of Plastic
Surgery located in 18 metropolitan markets throughout the United States. In the
future we intend to provide business services and acquire certain assets of, or
to manage, additional plastic surgery practices. In addition, we may acquire
companies, businesses or assets that compliment or expand our existing business.
We may expand our business into the performance of nonsurgical, noninvasive
procedures. In the future we intend to provide business services and acquire
certain assets of, or to manage, additional plastic surgery practices. Our
Internet strategy is important to our business. We have two proprietary
websites: www.Idealme.com, our consumer website, and
www.ThePlasticSurgeryCo.com, our surgeon website. Idealme.com allows consumers
to research available procedures, submit inquiries regarding cosmetic surgery
procedures, view possible cosmetic changes through online imaging technology,
obtain financing for procedures and locate board-certified cosmetic surgeons.
ThePlasticSurgeryCo.com will provide allied surgeons online access to our
national buying programs and facilitate "best practices" study groups among our
allied surgeons. We did not conduct any significant operations or earn any
revenue until the close of our initial public offering on December 15, 1999.
We earn revenue from providing services to the allied practices pursuant to
the business services agreements on a monthly basis as each practice collects
its cash. The business services agreements provide that each practice will pay
our fees based on a percentage of the net cash collected by that practice. Our
revenue consists of the sum of the service fee and amounts equal to the
operating expenses of the practice assumed by us under the business services
agreements. We separately disclose in the notes to our financial statements the
revenue from service fees and operating expenses. The operating expenses of the
practice that are our responsibility and which we are legally obligated to pay
include the following:
o salaries, benefits, payroll taxes, workers compensation, health
insurance and other benefit plans, and other direct expenses of
non-medical employees that are our employees located at the practice;
o direct costs of all employees or consultants that provide services to
each practice's office;
o medical and office supplies;
o lease or rent payments, utilities, telephone and maintenance expenses
for practice facilities;
o property taxes on our assets located at the practice offices;
o property, casualty and liability insurance premiums, excluding
malpractice insurance which is the responsibility of the practice;
o surgeon recruiting expenses; and
o advertising and expenses attributable to the promotion of practice
offices.
We assume all of the above expenses and will pay the third-party provider
of the goods and services. These expenses have been recorded in our financial
statements as expenses because we are legally obligated to pay them. In exchange
for assuming these expenses and providing business services, we have recorded
revenue in amounts equal to the assumed expenses plus the service fee described
above.
9
<PAGE>
The practice retains the responsibility for payment of any and all direct
employment expenses, including benefits, for any surgeon or other employee that
we are prohibited from employing by applicable law. In addition, the practice
retains responsibility for the payment of expenses for continuing education,
seminars, professional licenses, professional membership dues and malpractice
insurance and all other expenses of any surgeon. These expenses that remain the
responsibility of the practice are not included in reimbursed operating expenses
that is a component of our revenue.
POSSIBLE SOURCES OF FUTURE REVENUES
In the future, we also intend to enter into "management services
agreements," rather than "business services agreements," with select plastic
surgery practices. Pursuant to management services agreements, we will provide
business development services and Internet solutions and receive service fees.
The expenses we expect to incur under the management services agreements will be
substantially the same as the expenses we expect to incur under the business
services agreements. We will recognize revenues from these agreements based on a
percentage of the net cash collected by the allied practice which is
commensurate with the level and timing of services being provided. We will not
acquire operating assets of allied practices entering into management services
agreements, and we will not assume the operating expenses of these practices.
Because we will not assume the operating expenses of the practices entering into
management services agreements, we will not record the operating expenses as
revenue or expense in our income statement.
We list on our www.Idealme.com website cosmetic surgeons who are not allied
with us and are located in areas where we are not affiliated with an allied
practice. After a few months, we will contact these surgeons to determine
whether they want to continue to be listed in our directory. If so, we intend to
enter into subscription agreements with these surgeons to allow them to continue
to be included in the directory of board-certified or board-eligible cosmetic
surgeons on the www.Idealme.com. These subscribing surgeons listed on our
website directory will be listed for the convenience of potential consumers
located in areas where we are not affiliated with an allied practice. We will
not investigate the qualifications of the surgeons who subscribe for this
service. Our website will advise consumers to independently investigate each
surgeon's qualifications. Subscribing surgeons will pay us a fee for the
directory listing, which we will recognize as revenue as it is earned. We may
generate future revenues from the sale of products and services through our
proprietary websites. The revenue generated may include fees from banner and
sponsorship advertising, subscriptions to our online magazine and video imaging.
RESULTS OF OPERATIONS
For the three months ended March 31, 2000 we had net income of $365,297 on
operating revenues of $7,638,518, as compared to a loss of $438,491 for the same
period in 1999. In 1999, we were in a development stage and conducted no
operations and earned no revenues.
Net Revenues. Net revenues for the period ending March 31, 2000 were
$7,638,518, including $1,325,989 in service fees from the allied practices. Net
revenues include the service fees earned plus the operating expenses of the
practices assumed by us pursuant to the business services agreements.
Direct Expenses. Direct expenses represent certain operating costs incurred
by the allied practices that we assumed pursuant to the business services
agreements.
Salaries, Wages and Benefits. Salary, wage and benefit expenses represent
all costs of employees and consultants incurred during the three months ended
March 31, 2000. Headcount was increased from seven to fourteen during the
quarter, and will continue to grow as required to provide marketing and
administrative services to the allied practices.
General Operating Expenses. General operating expenses include $2,200,033
of reimbursed practice expenses and $286,552 of Corporate operating costs
incurred during the quarter ended March 31, 2000.
Depreciation and Amortization. For the three months ended March 31, 2000,
depreciation on corporate assets was $59,561. Amortization expense of $168,346
related to intangible assets was recorded as a result of allied practice
acquisitions.
10
<PAGE>
Interest expense
Interest expense of $119,118 was recorded during the three months ended
March 31, 2000 related to the interest portion of note payments to allied
practices. These notes were issued as part of the consideration to the allied
practices from the acquisition on December 15, 1999.
Provision for income taxes
We recorded a provision of $36,424 for income taxes for the three-month
period ended March 31, 2000. This reflects using a net operating loss
carryforwards from 1999 to offset taxable income. The provision reflects
primarily a provision for state taxes.
LIQUIDITY AND CAPITAL RESOURCES
Prior to our initial public offering, we financed our start-up costs
primarily through private sales of our securities. Our lack of operating history
resulted in our inability to obtain bridge financing and required us to raise
funds through the issuance of warrants. On May 13, 1999, we sold 1,390,204
warrants to existing shareholders for $0.50 per warrant. The warrants have an
exercise price of $2.50 and were fully vested on the date of issuance. We
recorded the excess of the fair value of the warrants of approximately $9.3
million as a charge to additional paid-in capital because the warrants were a
cost of raising funds for our operations. We received cash proceeds of
approximately $304,000 and the release of liabilities associated with accrued
compensation of approximately $391,000 as payment for the $0.50 purchase price
of the warrants. The non-cash proceeds from the offering were used to offset
accrued compensation of approximately $391,000 and the cash proceeds of
approximately $304,000 were used to fund our operating expenses, primarily rent
and related expenses, travel, advertising, development and professional
services.
Pursuant to our registration statement on Form S-1 declared effective on
December 2, 1999, we offered and sold 1,400,000 shares of common stock in our
initial public offering for an aggregate offering price of $11,200,000. As of
December 31, 1999, the amount of expenses we incurred in connection with the
issuance and distribution of the stock in our initial public offering was (1)
$1,120,000 for underwriting discounts and commissions, and (2) approximately
$1,547,000 for legal, accounting, printing, filing fees and miscellaneous costs.
We have used the remaining net proceeds of $8,533,000 to pay the cash portion of
the consideration to the founding practices, to service the debt payments of the
notes issued as part of the consideration to the allied practices, to repay
indebtedness assumed from certain allied practices, and to pay certain accrued
liabilities and for working capital.
The Company's primary working capital requirements will be funded through
cash from operating activities. Cash flows from investing activities were used
to purchase property and equipment, and cash flows from financing activities
were used for payment of debt to allied practices.
As of March 31, 2000, we had a working capital deficit of approximately
$3,206,000. The majority of the current liabilities relate to amounts owed to
employees and consultants who have agreed to defer payment until we acquire
financing. We will require capital for the following purposes:
o to pay accrued salaries and consulting fees of our employees or
consultants;
o to pay amounts owed to allied practices pursuant to notes issued in the
acquisitions of the founding practices;
o to pay amounts owed to our chairman pursuant to a $1,050,000 promissory
note;
o to pay, if necessary, operating expenses;
o to form additional affiliations with plastic surgery practices;
o to pay costs associated with the development and maintenance of our
websites; and
o to fund corporate costs for providing business services.
Each note issued in the acquisitions of the founding practices bears
interest at 8% per annum and provides for equal monthly payments of principal
and interest over the five-year term of the note.
11
<PAGE>
Each business services agreement obligates us, with no limitation, to pay
the operating expenses of the allied practice. These operating expenses are paid
out of individual practice cash accounts that we control. To the extent a
practice's operating expenses exceed its revenues, we are required to pay any
excess expense but the allied practice is obligated to repay this amount to us
with interest. We will record this amount as a receivable from the practice
bearing interest at the prime rate as published in THE WALL STREET JOURNAL plus
one percent. As of March 31, 2000, no receivable for funding excess operating
expenses existed from the allied practices. If it does occur, the allied
practice will be required to repay any receivable to us out of its future
revenues. The receivable will be repaid after the payment of the service fee and
before the allied surgeon receives any compensation. There is no defined payment
date related to the receivable. We intend to fund these excess operating
expenses from working capital or borrowings under a credit facility. Since
approximately 75% of the procedures performed by our allied surgeons are
cosmetic with fees generally paid no later than the time the procedure is
performed, we believe that our requirement to finance the excess operating
expenses of the allied practices can be funded through our operations. In
addition, our allied practices must pay our service fees and their operating
expenses before the surgeons receive any funds from the practice. We do not
believe that a lag in collections of patient receivables would occur or if it
occurred would significantly affect our liquidity.
We believe that cash flow from operations will be sufficient to fund our
ongoing operations through the terms of the business services agreements.
However, if the cash flow from operations is insufficient to satisfy our
liquidity requirements, we may need to sell additional equity or debt securities
or acquire a credit facility. We also believe that anticipated borrowings under
a credit facility will be sufficient to fund our planned capital needs for the
next 12 months. The Company is actively seeking a credit facility. Our business
plan involves an aggressive strategy of acquiring additional medical practices.
To the extent we are unable to obtain a credit facility, we may not be able to
fully implement our acquisition program. As of March 31, 2000, the Company has
not obtained a credit facility.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Foreign Exchange. To date, all of the Company's revenue from operations has
exclusively been denominated in United States dollars. In the future, the
Company may acquire practices outside the United States whose expenses and
revenues are priced in currencies other than the United States dollar. If this
occurs, fluctuations in the values of the respective currencies in which the
Company incurs expenses or generates revenues could adversely affect the
Company. Due to the constantly changing currency exposures and the volatility of
currency exchange rates, there can be no assurance that the Company would not
experience currency losses in the future, nor can the Company predict the effect
of exchange rate fluctuations upon future operating results. In the event the
Company conducts transactions in currencies other than the United States dollar,
we intend to carefully evaluate our currency management policies. If management
deems it appropriate, the Company may consider hedging a portion of any currency
exposure in the future.
Interest Rates. The Company invests its surplus cash in a variety of
financial instruments, consisting principally of bank time deposits and
short-term marketable securities with maturities of less than one year. The
Company's investment securities are held for purposes other than trading. The
Company accounts for its investment instruments in accordance with Statement of
Financial Accounting Standards No. 115, "Accounting for Certain Investments in
Debt and Equity Securities" ("SFAS 115"). All of the cash equivalent and
short-term investments are treated as "available for sale" under SFAS 115.
Investments in both fixed rate and floating rate interest earning instruments
carry a degree of interest rate risk. Fixed rate securities may have their fair
market value adversely impacted due to a rise in interest rates, while floating
rate securities may produce less income than expected if interest rates fall.
Due in part to these factors, the Company's future investment income may fall
short of expectations due to changes in interest rates or the Company may suffer
losses in principal if forced to sell securities which have seen a decline in
market value due to changes in interest rates. The Company may also face
interest rate risk exposure in connection with debt issued in connection with
the Company's acquisition strategy.
12
<PAGE>
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
We are not a party to any litigation that if adversely determined would
have a material adverse effect on our operations. Many of the founding practices
have pending litigation arising in the ordinary course of business. If we
acquired the stock of a practice in a stock purchase or merger transaction, we
assume the liabilities of the practice from a financial perspective, including
litigation, prior to the transaction. We intend to vigorously defend any and all
litigation. We maintain general liability insurance for us and on behalf of our
allied practices and, where permitted by applicable law and insurers, we will be
named as an additional insured under the policies of the allied practices. The
allied surgeons maintain professional liability insurance covering the delivery
of health services. Also, we are indemnified under the business services
agreements for liabilities we incur as a result of the performance of medical
services by allied surgeons. Successful malpractice claims against allied
practices could have a material adverse effect on our profitability. Although we
believe we have adequate liability insurance coverage, there can be no assurance
that a pending or future claim or claims will not be successful or, if
successful, will not exceed the limits of available insurance coverage. There
can also be no assurance that coverage will continue to be available at
acceptable costs and on favorable terms.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits
See exhibit index on page 15
(b) Reports on Form 8-K
The Company did not file any reports on Form 8-K during the quarter ended
March 31, 2000.
13
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the 1934 Act, we
have duly caused this Form 10-Q to be signed on behalf of the undersigned,
thereunto duly authorized, on May 8, 2000.
THE PLASTIC SURGERY COMPANY
By: /S/ Dennis E. Condon
-----------------------------------------------
Dennis E. Condon
President, Chief Executive Officer and Director
Pursuant to the requirements of the 1934 Act, this report has been signed
below by the following persons in the capacities indicated and on the date
indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
- --------- ----- ----
<S> <C> <C>
/S/ Jonathan Wilfong Chairman of the Board May 8, 2000
- --------------------------------------------
Jonathan Wilfong
/S/ Dennis Condon President and Chief May 8, 2000
- -------------------------------------------- Executive Officer (Principal
Dennis Condon Executive Officer)
/S/ Gunnar Sundstrom Chief Financial Officer May 8, 2000
- -------------------------------------------- (Principal Accounting
Gunnar Sundstrom Officer)
/S/ Robert Ersek Director May 8, 2000
- --------------------------------------------
Robert Ersek, M.D.
/S/ John Schantz Director May 8, 2000
- --------------------------------------------
John Schantz, M.D.
/S/ W. Grant Stevens Director May 8, 2000
- --------------------------------------------
W. Grant Stevens, M.D.
/S/ Mark A. Kaiser Director May 8, 2000
- --------------------------------------------
Mark A. Kaiser
/S/ William Armiger Director May 8, 2000
- --------------------------------------------
William Armiger, M.D.
</TABLE>
14
<PAGE>
<TABLE>
EXHIBIT INDEX
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
------ --------------------------------------------------------------------------------
<S> <C>
2.1 Form of Agreement and Plan of Reorganization between the Company and the
Founding Practices [A]
2.2 Form of Amendment to the Form of Agreement and Plan of Reorganization between
the Company and the Founding Practices [A]
2.3 Form of Purchase and Sale Agreement between the Company and the Founding
Practices [A]
2.4 Form of Stock Purchase and Sale Agreement between the Company and the Founding
Practices [A]
2.5 Letter Agreement between the Company and Isis Cosmetic Surgery Partners, Inc.
dated May 13, 1999 [A]
2.6 Form of Amendment to Agreement and Plan of Reorganization
dated as of November 11, 1999 between the Company and the
Founding Practices [A]
2.7 Form of Amendment to Purchase and Sale Agreement dated as of November 11, 1999
between the Company and the Founding Practices [A]
2.8 Form of Amendment to Agreement and Plan of Reorganization dated as of November
24, 1999 between the Company and Founding Practices [A]
2.9 Form of Amendment to Purchase and Sale Agreement dated as of November 24, 1999
between the Company and Founding Practices [A]
3.1 Form of Amended and Restated Articles of Incorporation [A]
3.2 Form of Amended and Restated Bylaws [A]
4.1 Specimen Common Stock Certificate [A]
4.2 Form of Warrant Agreement between the Company and the representatives of the
underwriters of the Company's initial public offering [A]
4.3 Form of Referral Warrant [A]
10.1 Amendment to Employment Agreement between the Company and David Challoner dated
February 25, 1999 [A]
10.2 Amendment to Employment Agreement between the Company and Patricia Altavilla
dated March 1, 1999 [A]
10.3 Form of Service Agreement between the Company and the Founding Practices [A]
10.4 Form of Amendment to Form of Service Agreement between the Company and the
Founding Practices [A]
10.5 Form of Consulting and Business Services Agreement between the Company and the
Founding Practices [A]
10.6 Form of Employment Agreement between the allied surgeons and the allied
practices [A]
10.7 1998 Employee Stock Option Plan [A]
10.8 1999 Non-Employee Director Stock Plan [A]
10.9 Amendment to Employment Agreement between the Company and Dennis E. Condon dated
June 30, 1999 [A]
10.10 Employment Agreement between the Company and Joshua Levine dated February 1,
2000 [B]
27.1 Financial Data Schedule (for SEC use only).
</TABLE>
- -----------------
[A] Incorporated by reference to the Company's Registration on Form S-1, File
No. 333-78565.
[B] Incorporated by reference to the Company's Annual Report on Form 10-K for
the year ended December 31, 1999 filed March 30, 2000, File No. 1-15431.
15
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.
<TABLE> <S> <C>
THE PLASTIC SURGERY COMPANY
Filed on May 10, 2000
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF THE PLASTIC SURGERY COMPANY FOR THE THREE MONTHS ENDED
MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 374,317
<SECURITIES> 0
<RECEIVABLES> 797,744
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 1,206,648
<PP&E> 1,231,221
<DEPRECIATION> (100,820)
<TOTAL-ASSETS> 11,392,193
<CURRENT-LIABILITIES> 4,412,604
<BONDS> 0
0
0
<COMMON> 0
<OTHER-SE> 3,024,892
<TOTAL-LIABILITY-AND-EQUITY> 11,392,193
<SALES> 0
<TOTAL-REVENUES> 7,638,518
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 7,124,824
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 119,118
<INCOME-PRETAX> 401,721
<INCOME-TAX> 36,424
<INCOME-CONTINUING> 365,297
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 365,297
<EPS-BASIC> 0.08
<EPS-DILUTED> 0.08
</TABLE>
